Agilent Technologies, Inc. (A)

Over the past six months, Agilent Technologies' stock has experienced some fluctuations and notable events. Agilent reported third-quarter fiscal 2025 earnings of $1.37 per share, beating estimates, with revenues of $1.74 billion. The company concluded its fiscal year 2025 with revenue of $1.86 billion for the fourth quarter, exceeding guidance. Agilent reported a drop in Q1 profit and missed both earnings and revenue estimates for the first quarter of fiscal year 2026. The company authorized up to $2 billion for stock repurchases and repurchased $164 million in stock. Padraig McDonnell assumed the role of President, CEO, and Director in 2024, succeeding Michael McMullen, and Rodney Gonsalves was appointed interim CFO, with Pascal Soriot and Judy Gawlik Brown elected to the board on May 21, 2025. The stock price as of February 27, 2026, was $121.38 per share, representing a decline of 5.11% from February 28, 2025.

While explicit details on demand seasonality for Agilent Technologies' products and services are not extensively detailed, the company's business model suggests some resilience to economic cycles. Agilent has built a significant portion of its revenue stream from services and consumables, which are economically tied to its installed base of instruments. Demand for precision analysis is generally rising across Agilent's key end markets, including pharma/biotech R&D, diagnostics, food/environment testing, and advanced materials. The company's involvement in GLP-1 peptide drugs also represents a growing demand driver.

Agilent Technologies, Inc. is a global leader in the life sciences, diagnostics, and applied chemical markets, providing instruments, software, services, and consumables for laboratories worldwide. The company operates within the healthcare equipment and services sector and is also a notable player in the laboratory supply wholesaling industry. Agilent's mission is to advance the quality of life by focusing its expertise on critical areas such as pharmaceutical research, drug development, environmental analysis, patient diagnostics, and ensuring the safety of water, food, and pharmaceuticals. Agilent's major products and solutions include liquid chromatography systems used for separating, identifying, and quantifying components in mixtures; mass spectrometers for identifying chemical substances; gas chromatography systems for analyzing volatile compounds; DNA/RNA microarray solutions for analyzing gene expression; cell analysis instruments for studying cell behavior; diagnostic kits and reagents for disease detection; laboratory software solutions for enhancing lab efficiency; lab management services offering consulting and equipment maintenance; and various analytical platforms encompassing spectroscopy, lab automation, and bioreagents.

Agilent Technologies maintains a significant global presence, serving customers in 110 countries with approximately 18,000 employees worldwide. The company's global footprint includes sales offices, logistics centers, and business facilities across three major geographies: the Americas, with headquarters in Santa Clara, California, and other key locations; Europe, with significant operations in Waldbronn, Germany, Glostrup, Denmark, and Turin, Italy; and Asia Pacific, with a strong presence in Shanghai and Beijing, China, Tokyo, Japan, Singapore, Penang, Malaysia, Melbourne, Australia, and Manesar-Gurgaon, India.

Agilent Technologies is recognized for its uncompromising integrity and commitment to advancing scientific discovery. The company's brand reputation has been positively influenced by innovative product launches, such as the S540MD Slide Scanner System, expanding R&D capabilities, including a LEED Platinum-certified campus in India, strategic collaborations, such as with Wasatch BioLabs, a focus on automation, demonstrated at conferences like SLAS2026, FDA approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC), and the acquisition of BIOVECTRA.

Agilent Technologies' ownership is heavily concentrated among institutional investors, who hold over 91% of the company's stock as of August 2025. Institutional investors typically hold over 80% of the outstanding shares, influencing company strategy. Insider ownership remains minimal, at around 0.20%. Major institutional owners include Vanguard Group, Inc., BlackRock, Inc., Massachusetts Financial Services Co /ma/, State Street Corp, Wellington Management Group LLP, Geode Capital Management, LLC, T. Rowe Price Investment Management, Inc., Morgan Stanley, Pictet Asset Management Holding SA, Deutsche Bank Ag, Generation Investment Management, and DWS Investment GmbH.